Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1373/clinchem.2019.306175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarker profiles that differentiate type-1 and type 2 myocardial infarction.
Heart Lung
January 2025
University of Foggia, Department of Medical and Surgical Sciences, Foggia, Italy. Electronic address:
Background: It is crucial to distinguish type-1 myocardial infarction (T1MI) from type-2 myocardial infarction (T2MI) at admission and during hospitalization to avoid unnecessary invasive exams and inappropriate admissions to the acute cardiac care unit.
Objectives: The purpose of the study was to define a simple profile derived from commonly used biomarkers to differentiate T1MI from T2MI.
Methods: We prospectively enrolled in an observational study 213 iconsecutive patients with a provisional diagnosis of non-ST-elevation acute myocardial infarction (NSTEMI) admitted to the Cardiology Department.
Two-hit mouse model of heart failure with preserved ejection fraction combining diet-induced obesity and renin-mediated hypertension.
Sci Rep
January 2025
Cardiovascular Institute, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Heart failure with preserved ejection fraction (HFpEF) is increasingly common but its pathogenesis is poorly understood. The ability to assess genetic and pharmacologic interventions is hampered by the lack of robust preclinical mouse models of HFpEF. We developed a novel "two-hit" model, which combines obesity and insulin resistance with chronic pressure overload to recapitulate clinical features of HFpEF.
View Article and Find Full Text PDFShining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.
J Manag Care Spec Pharm
January 2025
PRIME Education, New York City, NY.
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a complex condition in which 2 consequential diseases interact and increase negative outcomes. Although the pathophysiologic mechanisms of PH-ILD are not yet well understood, the pronounced effect on functional status, supplemental oxygen requirements, health care resource utilization, and mortality that frequently accompany this diagnosis are well documented. A critical feature that complicates pathophysiologic understanding of PH-ILD is that progression of the pulmonary vascular disease does not always appear to be driven by the underlying lung disease.
View Article and Find Full Text PDFShort-Term Oral Administration of the Porcupine Inhibitor, Wnt-c59, Improves the Structural and Functional Features of Experimental HFpEF.
Pharmacol Res Perspect
February 2025
School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, UK.
Article Synopsis
- HFpEF makes up about 50% of heart failure cases globally, increasing due to longer lifespans and more health issues.
- Wnt signaling is linked to heart problems like cardiomyocyte hypertrophy and fibrosis, and PORCN inhibitors (like Wnt-c59) show promise in improving heart function.
- In a study, Wnt-c59 reduced adverse heart changes and improved heart function in mice with HFpEF, even though Wnt signaling itself wasn't activated in their hearts.
Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China.
Rev Cardiovasc Med
December 2024
Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China.
Background: Real-world data on the clinical benefit of vericiguat are currently limited. This multicenter, real-world study was conducted to evaluate the clinical characteristics and therapeutic effects of vericiguat in real-world settings.
Methods: This study analyzed heart failure (HF) patients who initiated vericiguat treatment from September 2022 to August 2023 across nine hospitals in the Anhui Province, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!